Ranitidine (INN) (pronounced ) is a histamine H2-receptor antagonist
that inhibits stomach acid production. It is commonly used in the
treatment of peptic ulcer disease (PUD) and gastroesophageal reflux
disease (GERD). It is currently marketed over the counter under
the trade name Zinetac and Zantac by GlaxoSmithKline and by many
other companies under various other names.
Ranitidine bismuth comes as a tablet to take by mouth. It usually is taken twice a day with or without food. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take ranitidine bismuth exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.Certain preparations of ranitidine are available over the counter (OTC) in various countries. In the United States, 75 mg and 150 mg tablets are available OTC. In Australia, packs containing 7 or 14 doses of the 150 mg tablet are available in supermarkets, small packs of 150 mg and 300 mg tablets are Schedule 2 Pharmacy Medicines. Larger doses and pack sizes still require a prescription.
The possible side effects that may occur during treatment with Ranitidine HCT are: constipation, diarrhea, nausea/vomiting, abdominal discomfort/pain, headache.
Reproduction studies have been performed in rats and rabbits at doses up to 160 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to ZANTAC. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
There has been limited experience with overdosage. Reported acute ingestions of up to 18 g orally have been associated with transient adverse effects similar to those encountered in normal clinical experience (see ADVERSE REACTIONS). In addition, abnormalities of gait and hypotension have been reported.
When overdosage occurs, the usual measures to remove unabsorbed material from the gastrointestinal tract, clinical monitoring, and supportive therapy should be employed.